Home Applications 209091 Application 209091
Type NDA
Sponsor ASTRAZENECA AB Application Products# Product, Drug, Ingredient table Product Drug Ingredient Form Strength Reference drug Reference standard 001 QTERN DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE TABLET;ORAL 10MG;EQ 5MG BASE Yes Yes 002 QTERN DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE TABLET;ORAL 5MG;EQ 5MG BASE Yes No
Source provenance: Browse the complete Orange Book source catalog · source snapshot 45 .
Orange Book products# Current product rows page 1 of 1 · 2 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N209091-001 QTERN DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE 10MG;EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** TABLET / ORAL RLD 2017-02-27 N209091-002 QTERN DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE 5MG;EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** TABLET / ORAL RLD 2019-05-02
Orange Book patents# Current patent rows page 1 of 1 · 28 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N209091-001 6515117 2025-10-04 U-493 Drug substance, Drug product 2017-03-22 N209091-001 6515117*PED 2026-04-04 Pediatric extension N209091-001 8501698 2027-06-20 U-1976 Drug product 2017-03-22 N209091-001 8501698 2027-06-20 U-1977 Drug product 2017-03-22 N209091-001 8501698 2027-06-20 U-493 Drug product 2017-03-22 N209091-001 8501698*PED 2027-12-20 Pediatric extension N209091-001 8221786 2028-03-21 Drug product 2017-03-22 N209091-001 8361972 2028-03-21 U-1976 2017-03-22 N209091-001 8361972 2028-03-21 U-1977 2017-03-22 N209091-001 8361972 2028-03-21 U-493 2017-03-22 N209091-001 8716251 2028-03-21 Drug product 2017-03-22 N209091-001 8221786*PED 2028-09-21 Pediatric extension N209091-001 8361972*PED 2028-09-21 Pediatric extension N209091-001 8716251*PED 2028-09-21 Pediatric extension N209091-001 7919598 2029-12-16 Drug substance 2017-03-22 N209091-001 7919598*PED 2030-06-16 Pediatric extension N209091-002 6515117 2025-10-04 U-493 Drug substance, Drug product 2019-05-24 N209091-002 6515117*PED 2026-04-04 Pediatric extension N209091-002 8501698 2027-06-20 U-493 Drug product 2019-05-24 N209091-002 8501698*PED 2027-12-20 Pediatric extension N209091-002 8221786 2028-03-21 Drug product 2019-05-24 N209091-002 8361972 2028-03-21 U-493 2019-05-24 N209091-002 8716251 2028-03-21 Drug product 2019-05-24 N209091-002 8221786*PED 2028-09-21 Pediatric extension N209091-002 8361972*PED 2028-09-21 Pediatric extension N209091-002 8716251*PED 2028-09-21 Pediatric extension N209091-002 7919598 2029-12-16 Drug substance 2019-05-24 N209091-002 7919598*PED 2030-06-16 Pediatric extension
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 2 of 3 · 90 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2022-04-04 05:41 UTC 2022-04 N209091-001 QTERN 10MG;EQ 5MG BASE TABLET / ORAL RLD, RS 2017-02-27 4b0b4de00fa7…2022-04-04 05:41 UTC 2022-04 N209091-002 QTERN 5MG;EQ 5MG BASE TABLET / ORAL RLD 2019-05-02 4b0b4de00fa7…2019-12-13 00:20 UTC 2019-12 N209091-001 QTERN 10MG;EQ 5MG BASE TABLET / ORAL RLD, RS 2017-02-27 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N209091-002 QTERN 5MG;EQ 5MG BASE TABLET / ORAL RLD 2019-05-02 74a2ff9319b5…2022-03-09 01:35 UTC 2022-03 N209091-001 QTERN 10MG;EQ 5MG BASE TABLET / ORAL RLD, RS 2017-02-27 bb7c543d1eb4…2022-03-09 01:35 UTC 2022-03 N209091-002 QTERN 5MG;EQ 5MG BASE TABLET / ORAL RLD 2019-05-02 bb7c543d1eb4…2021-12-28 21:50 UTC 2021-12 N209091-001 QTERN 10MG;EQ 5MG BASE TABLET / ORAL RLD, RS 2017-02-27 782e0a99824c…2021-12-28 21:50 UTC 2021-12 N209091-002 QTERN 5MG;EQ 5MG BASE TABLET / ORAL RLD 2019-05-02 782e0a99824c…2021-05-05 16:15 UTC · 3 captures of this ZIP 2021-05 N209091-001 QTERN 10MG;EQ 5MG BASE TABLET / ORAL RLD, RS 2017-02-27 87673890dc5c…2021-05-05 16:15 UTC · 3 captures of this ZIP 2021-05 N209091-002 QTERN 5MG;EQ 5MG BASE TABLET / ORAL RLD 2019-05-02 87673890dc5c…2021-03-12 10:30 UTC 2021-03 N209091-001 QTERN 10MG;EQ 5MG BASE TABLET / ORAL RLD, RS 2017-02-27 5aa47cf7b7d7…2021-03-12 10:30 UTC 2021-03 N209091-002 QTERN 5MG;EQ 5MG BASE TABLET / ORAL RLD 2019-05-02 5aa47cf7b7d7…2020-12-22 03:56 UTC 2020-12 N209091-001 QTERN 10MG;EQ 5MG BASE TABLET / ORAL RLD, RS 2017-02-27 8869cabd3fbd…2020-12-22 03:56 UTC 2020-12 N209091-002 QTERN 5MG;EQ 5MG BASE TABLET / ORAL RLD 2019-05-02 8869cabd3fbd…2020-11-12 02:37 UTC 2020-11 N209091-001 QTERN 10MG;EQ 5MG BASE TABLET / ORAL RLD, RS 2017-02-27 c0c555d07b60…2020-11-12 02:37 UTC 2020-11 N209091-002 QTERN 5MG;EQ 5MG BASE TABLET / ORAL RLD 2019-05-02 c0c555d07b60…2019-12-14 00:12 UTC 2019-12 N209091-001 QTERN 10MG;EQ 5MG BASE TABLET / ORAL RLD, RS 2017-02-27 3f01610625f2…2019-12-14 00:12 UTC 2019-12 N209091-002 QTERN 5MG;EQ 5MG BASE TABLET / ORAL RLD 2019-05-02 3f01610625f2…2019-09-15 20:21 UTC 2019-09 N209091-001 QTERN 10MG;EQ 5MG BASE TABLET / ORAL RLD, RS 2017-02-27 b00525d2431f…2019-09-15 20:21 UTC 2019-09 N209091-002 QTERN 5MG;EQ 5MG BASE TABLET / ORAL RLD 2019-05-02 b00525d2431f…2019-07-19 19:46 UTC 2019-07 N209091-001 QTERN 10MG;EQ 5MG BASE TABLET / ORAL RLD, RS 2017-02-27 ea99ee380514…2019-07-19 19:46 UTC 2019-07 N209091-002 QTERN 5MG;EQ 5MG BASE TABLET / ORAL RLD 2019-05-02 ea99ee380514…2024-03-16 18:09 UTC · 4 captures of this ZIP 2024-03 N209091-001 QTERN 10MG;EQ 5MG BASE TABLET / ORAL RLD, RS 2017-02-27 6a51e52b5d6a…2024-03-16 18:09 UTC · 4 captures of this ZIP 2024-03 N209091-002 QTERN 5MG;EQ 5MG BASE TABLET / ORAL RLD 2019-05-02 6a51e52b5d6a…2024-02-18 07:12 UTC 2024-02 N209091-001 QTERN 10MG;EQ 5MG BASE TABLET / ORAL RLD, RS 2017-02-27 1c564ffb4f44…2024-02-18 07:12 UTC 2024-02 N209091-002 QTERN 5MG;EQ 5MG BASE TABLET / ORAL RLD 2019-05-02 1c564ffb4f44…2023-12-20 04:57 UTC 2023-12 N209091-001 QTERN 10MG;EQ 5MG BASE TABLET / ORAL RLD, RS 2017-02-27 ea1830bbd6c7…2023-12-20 04:57 UTC 2023-12 N209091-002 QTERN 5MG;EQ 5MG BASE TABLET / ORAL RLD 2019-05-02 ea1830bbd6c7…2023-11-28 05:40 UTC · 2 captures of this ZIP 2023-11 N209091-001 QTERN 10MG;EQ 5MG BASE TABLET / ORAL RLD, RS 2017-02-27 a72a2bbeb626…2023-11-28 05:40 UTC · 2 captures of this ZIP 2023-11 N209091-002 QTERN 5MG;EQ 5MG BASE TABLET / ORAL RLD 2019-05-02 a72a2bbeb626…2023-10-25 00:34 UTC · 2 captures of this ZIP 2023-10 N209091-001 QTERN 10MG;EQ 5MG BASE TABLET / ORAL RLD, RS 2017-02-27 9b2671bbb829…2023-10-25 00:34 UTC · 2 captures of this ZIP 2023-10 N209091-002 QTERN 5MG;EQ 5MG BASE TABLET / ORAL RLD 2019-05-02 9b2671bbb829…2023-07-15 15:27 UTC · 2 captures of this ZIP 2023-07 N209091-001 QTERN 10MG;EQ 5MG BASE TABLET / ORAL RLD, RS 2017-02-27 a67488948f0b…2023-07-15 15:27 UTC · 2 captures of this ZIP 2023-07 N209091-002 QTERN 5MG;EQ 5MG BASE TABLET / ORAL RLD 2019-05-02 a67488948f0b…2023-06-13 01:57 UTC · 3 captures of this ZIP 2023-06 N209091-001 QTERN 10MG;EQ 5MG BASE TABLET / ORAL RLD, RS 2017-02-27 3f0d92c62455…2023-06-13 01:57 UTC · 3 captures of this ZIP 2023-06 N209091-002 QTERN 5MG;EQ 5MG BASE TABLET / ORAL RLD 2019-05-02 3f0d92c62455…2023-05-13 08:27 UTC 2023-05 N209091-001 QTERN 10MG;EQ 5MG BASE TABLET / ORAL RLD, RS 2017-02-27 053a50430f4f…2023-05-13 08:27 UTC 2023-05 N209091-002 QTERN 5MG;EQ 5MG BASE TABLET / ORAL RLD 2019-05-02 053a50430f4f…2023-01-26 05:58 UTC 2023-01 N209091-001 QTERN 10MG;EQ 5MG BASE TABLET / ORAL RLD, RS 2017-02-27 3bdfa0b2c4d7…2023-01-26 05:58 UTC 2023-01 N209091-002 QTERN 5MG;EQ 5MG BASE TABLET / ORAL RLD 2019-05-02 3bdfa0b2c4d7…
Observed Orange Book patent history# Patent history page 1 of 27 · 1,056 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-11-14 07:37:17 2026-10 N209091-001 6515117 2025-10-04 U-493 Drug substance, Drug product 2017-03-22 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N209091-001 6515117*PED 2026-04-04 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N209091-001 8501698 2027-06-20 U-1976 Drug product 2017-03-22 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N209091-001 8501698 2027-06-20 U-1977 Drug product 2017-03-22 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N209091-001 8501698 2027-06-20 U-493 Drug product 2017-03-22 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N209091-001 8501698*PED 2027-12-20 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N209091-001 8221786 2028-03-21 Drug product 2017-03-22 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N209091-001 8361972 2028-03-21 U-1977 2017-03-22 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N209091-001 8361972 2028-03-21 U-1976 2017-03-22 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N209091-001 8361972 2028-03-21 U-493 2017-03-22 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N209091-001 8716251 2028-03-21 Drug product 2017-03-22 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N209091-001 8221786*PED 2028-09-21 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N209091-001 8361972*PED 2028-09-21 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N209091-001 8716251*PED 2028-09-21 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N209091-001 7919598 2029-12-16 Drug substance 2017-03-22 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N209091-001 7919598*PED 2030-06-16 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N209091-002 6515117 2025-10-04 U-493 Drug substance, Drug product 2019-05-24 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N209091-002 6515117*PED 2026-04-04 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N209091-002 8501698 2027-06-20 U-493 Drug product 2019-05-24 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N209091-002 8501698*PED 2027-12-20 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N209091-002 8221786 2028-03-21 Drug product 2019-05-24 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N209091-002 8361972 2028-03-21 U-493 2019-05-24 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N209091-002 8716251 2028-03-21 Drug product 2019-05-24 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N209091-002 8221786*PED 2028-09-21 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N209091-002 8361972*PED 2028-09-21 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N209091-002 8716251*PED 2028-09-21 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N209091-002 7919598 2029-12-16 Drug substance 2019-05-24 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N209091-002 7919598*PED 2030-06-16 Pediatric extension d4dbc9d85df4…2026-10-15 13:18:30 2026-09 N209091-001 6515117 2025-10-04 U-493 Drug substance, Drug product 2017-03-22 c2088c7a36db…2026-10-15 13:18:30 2026-09 N209091-001 6515117*PED 2026-04-04 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N209091-001 8501698 2027-06-20 U-1976 Drug product 2017-03-22 c2088c7a36db…2026-10-15 13:18:30 2026-09 N209091-001 8501698 2027-06-20 U-1977 Drug product 2017-03-22 c2088c7a36db…2026-10-15 13:18:30 2026-09 N209091-001 8501698 2027-06-20 U-493 Drug product 2017-03-22 c2088c7a36db…2026-10-15 13:18:30 2026-09 N209091-001 8501698*PED 2027-12-20 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N209091-001 8221786 2028-03-21 Drug product 2017-03-22 c2088c7a36db…2026-10-15 13:18:30 2026-09 N209091-001 8361972 2028-03-21 U-1977 2017-03-22 c2088c7a36db…2026-10-15 13:18:30 2026-09 N209091-001 8361972 2028-03-21 U-1976 2017-03-22 c2088c7a36db…2026-10-15 13:18:30 2026-09 N209091-001 8361972 2028-03-21 U-493 2017-03-22 c2088c7a36db…2026-10-15 13:18:30 2026-09 N209091-001 8716251 2028-03-21 Drug product 2017-03-22 c2088c7a36db…2026-10-15 13:18:30 2026-09 N209091-001 8221786*PED 2028-09-21 Pediatric extension c2088c7a36db…
Observed Orange Book exclusivity history# Exclusivity history page 1 of 2 · 48 observed states.
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application# NDC listings for this application page 1 of 1 · 18 matching rows.
NDC, Name, Nonproprietary name table NDC Name Nonproprietary name Labeler Marketing category Status 0310-6770 QTERN dapagliflozin and saxagliptin AstraZeneca Pharmaceuticals LP NDA Current 0310-6770 QTERN dapagliflozin and saxagliptin AstraZeneca Pharmaceuticals LP NDA Current 0310-6770 QTERN dapagliflozin and saxagliptin AstraZeneca Pharmaceuticals LP NDA Current 0310-6770 QTERN dapagliflozin and saxagliptin AstraZeneca Pharmaceuticals LP NDA Current 0310-6770 QTERN dapagliflozin and saxagliptin AstraZeneca Pharmaceuticals LP NDA Current 0310-6770 QTERN dapagliflozin and saxagliptin AstraZeneca Pharmaceuticals LP NDA Current 0310-6770 QTERN dapagliflozin and saxagliptin AstraZeneca Pharmaceuticals LP NDA Current 0310-6770 QTERN dapagliflozin and saxagliptin AstraZeneca Pharmaceuticals LP NDA Current 0310-6780 QTERN dapagliflozin and saxagliptin AstraZeneca Pharmaceuticals LP NDA Current 0310-6780 QTERN dapagliflozin and saxagliptin AstraZeneca Pharmaceuticals LP NDA Current 0310-6780 QTERN dapagliflozin and saxagliptin AstraZeneca Pharmaceuticals LP NDA Current 0310-6780 QTERN dapagliflozin and saxagliptin AstraZeneca Pharmaceuticals LP NDA Current 0310-6780 QTERN dapagliflozin and saxagliptin AstraZeneca Pharmaceuticals LP NDA Current 0310-6780 QTERN dapagliflozin and saxagliptin AstraZeneca Pharmaceuticals LP NDA Current 0310-6780 QTERN dapagliflozin and saxagliptin AstraZeneca Pharmaceuticals LP NDA Current 0310-6780 QTERN dapagliflozin and saxagliptin AstraZeneca Pharmaceuticals LP NDA Current 0310-6780 QTERN dapagliflozin and saxagliptin AstraZeneca Pharmaceuticals LP NDA Current 0310-6780 QTERN dapagliflozin and saxagliptin AstraZeneca Pharmaceuticals LP NDA Current